Clinical Trials Browser

Interventional × Solid Tumors × Clear all

NCT05101070 2026-03-18

aCCeleR8-001

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumors

NCT05203172 2026-03-18

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Phase 4 Recruiting

Other solid neoplasm

Solid Tumors

NCT05155332 2026-03-17

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Phase 1 Recruiting

Other solid neoplasm

Solid Tumors

NCT06892379 2026-03-13

A Study of HS-20110 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Solid Tumors

NCT04261413 2026-03-11

Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

Other solid neoplasm

Solid Tumors

NCT07018622 2026-03-11

DAPA-ARMOR

Phase 2 Recruiting

Other solid neoplasm

Solid Tumors

NCT04589845 2026-03-06

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Phase 2 Recruiting

920 enrolled 1 FDA

Other solid neoplasm

Solid Tumors

NCT03313778 2026-03-04

KEYNOTE-603

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT03448042 2026-02-27

A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT07176975 2026-02-27

A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers

Phase 1 Not yet recruiting

Other solid neoplasm

Solid Tumors

NCT07030959 2026-02-25

Study of AUBE00 in Patients With Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Solid Tumors

NCT04250155 2026-02-24

An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT07181681 2026-02-23

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Solid Tumors

NCT07417501 2026-02-18

Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification

Phase 2 Not yet recruiting

Other solid neoplasm

Solid Tumors

NCT06651593 2026-02-17

Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

Phase 2 Recruiting

Other solid neoplasm

Solid Tumors

NCT07123103 2026-02-17

A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Solid Tumors

NCT07415031 2026-02-17

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Phase 2 Not yet recruiting

Other solid neoplasm

Solid Tumors

NCT06885281 2026-02-13

A Study of ZL-1310 in Participants With Selected Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumors

NCT02320435 2026-02-12

A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial

Phase 3 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT07407985 2026-02-12

GK01IIT-TZ03

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT03917381 2026-02-11

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT07395258 2026-02-09

A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Phase 1 Not yet recruiting

Other solid neoplasm

Solid Tumors

NCT05372367 2026-02-03

A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor

Phase 1 Completed

Other solid neoplasm

Solid Tumors

NCT05419375 2026-02-03

Screening Study for Participants With Malignant Tumors

Phase 2 Completed

Other solid neoplasm

Solid Tumors

NCT04627740 2026-01-20

Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors

Phase 1/2 Completed

Other solid neoplasm

Solid Tumors

NCT07351903 2026-01-20

GUARDIAN-02

Phase 1 Recruiting

Other solid neoplasm

Solid Tumors

NCT00777582 2026-01-13

Phase I Comparative Bioavailability Study

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT07312903 2026-01-12

DPTX3186 in Wnt Pathway Activated Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Solid Tumors

NCT07265622 2025-12-29

First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumors

NCT06227377 2025-12-24

QTX3034 in Patients With KRAS G12D Mutation

Phase 1 Recruiting

Other solid neoplasm

Solid Tumors

NCT05836324 2025-12-18

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Solid Tumors

NCT06727812 2025-12-18

Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Solid Tumors

NCT05471856 2025-12-17

A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

Phase 1 Recruiting

Other solid neoplasm

Solid Tumors

NCT07159126 2025-12-10

A Study of DS3610a in Participants With Advanced Solid Tumor

Phase 1 Recruiting

Other solid neoplasm

Solid Tumors

NCT07274085 2025-12-10

A Phase 1 Study of HDM2017 in Advanced Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Solid Tumors

NCT07105215 2025-11-26

A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumors

NCT07032077 2025-11-20

A Phase II Clinical Trial on the Safety, Tolerability, and Efficacy of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors.

Phase 2 Recruiting

Other solid neoplasm

Solid Tumors

NCT07231081 2025-11-17

Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Solid Tumors

NCT07178938 2025-11-14

THERANOVA

Phase 2 Not yet recruiting

BreastOther solid neoplasm

Solid Tumors

NCT07055594 2025-11-06

NbTAST-01

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumors

NCT05327946 2025-10-28

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT02597036 2025-10-23

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors

Phase 1 Terminated

62 enrolled 25 charts

Other solid neoplasm

Solid Tumors

NCT06873789 2025-10-15

A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT06066424 2025-10-14

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

Phase 1 Recruiting

Other solid neoplasm

Solid Tumors

NCT05976334 2025-10-06

An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors

Phase 1 Terminated

3 enrolled 19 charts

Other solid neoplasm

Solid Tumors

NCT06933524 2025-10-01

ATB-320-001A

Phase 1 Not yet recruiting

Other solid neoplasm

Solid Tumors

NCT06082960 2025-09-10

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT07158918 2025-09-08

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumors

NCT07128576 2025-09-04

Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid Tumors

Phase 2 Not yet recruiting

Other solid neoplasm

Solid Tumors

NCT04685226 2025-09-02

A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumors